A phase I study to assess the safety, tolerability, and pharmacokinetics of enteric-coated buprenorphine (BuTab) in healthy subjects

Trial Profile

A phase I study to assess the safety, tolerability, and pharmacokinetics of enteric-coated buprenorphine (BuTab) in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2016

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Opioid abuse; Pain
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Relmada Therapeutics
  • Most Recent Events

    • 11 Jan 2016 Top-line results will be presented at 2016 Biotech Showcase™ in San Francisco Presentation on January 13, 2016, as per Relmada Therapeutics media release.
    • 08 Dec 2015 According to Relmada Therapeutics media release, positive topline results of oral formulation of buprenorphine were announced.
    • 07 Dec 2015 According to a Relmada Therapeutics media release, data from this study are expected before the end of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top